MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental pill tested against seven rare blood diseases
Disease control CompletedThis study tested whether the drug dasatinib could help control several rare blood disorders including leukemia, myelofibrosis, and mastocytosis. Participants took dasatinib pills daily for as long as it helped control their disease. Researchers monitored blood counts and bone ma…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill targets tough blood cancers in major trial
Disease control CompletedThis study tested a new oral drug called pelabresib for people with advanced blood cancers like myelofibrosis. The first part aimed to find a safe dose. The second part tested if pelabresib, given alone or with another drug (ruxolitinib), could shrink enlarged spleens, reduce the…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
One donor, two transplants: experimental procedure aims to cure blood cancer and fix kidneys
Disease control CompletedThis pilot study tested a combined transplant from a partially matched family donor. It aimed to treat patients who had both a serious blood disorder (like leukemia) and advanced kidney disease at the same time. The goal was to cure the blood disorder and restore kidney function …
Matched conditions: MYELOFIBROSIS
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New drug tested for tough blood cancer cases
Disease control CompletedThis study tested a drug called itacitinib for people with a serious bone marrow cancer called myelofibrosis who had already tried other standard treatments. The main goals were to find a safe dose and see if the drug could reduce spleen size and improve symptoms. Only four peopl…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
Scientists test new combo against aggressive blood cancers
Disease control CompletedThis study tested a combination of two drugs, ruxolitinib and CPX-351, for patients with advanced forms of certain blood cancers that had worsened. The main goals were to find the safest dose of the combination and to see how well it worked to control the cancer. The trial involv…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC
-
Gentler transplant strategy tested for tough blood cancers
Disease control CompletedThis study tested a two-step, lower-intensity stem cell transplant for patients with high-risk blood cancers like leukemia and lymphoma. The goal was to use milder chemotherapy and radiation before the transplant to reduce side effects while still allowing the donor's immune cell…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC
-
First step: scientists test new blood disorder Drug's safety with common meds
Knowledge-focused CompletedThis early-stage study aimed to understand how a potential new drug for myelofibrosis (a bone marrow disorder) interacts with other common medications that can speed up or slow down drug processing in the body. It involved 40 healthy volunteers who received single doses of the st…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Researchers look back at how doctors treated blood cancer patients
Knowledge-focused CompletedThis study looked back at the medical records of 355 people in Turkey who were treated for myelofibrosis, a type of bone marrow cancer. The goal was to understand the real-world use of the drug ruxolitinib, including patient characteristics, treatment patterns, and side effects. …
Matched conditions: MYELOFIBROSIS
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:10 UTC